Clinical disclaimer: This article is for informational purposes only and does not constitute medical advice. Never start, stop, or change medication without clinical supervision.

Key Points

  • STEP UP showed semaglutide 7.2 mg pushed average weight loss past the 20% mark
  • 2.4 mg may not be the final word for all patients
  • A disappointing response to semaglutide is not automatically solved by escalating the dose
  • Higher dose does not address poor protein intake, low training stimulus or erratic adherence
  • The field is now competing at the margins of already strong efficacy

STEP UP matters because it asked whether more semaglutide works meaningfully better. The answer appears to be yes. Semaglutide 7.2 mg pushed average weight loss past the 20% mark. [1]

What the trial showed

STEP UP suggests that 2.4 mg may not be the final word for all patients. [1] But the trial does not mean every underwhelming response to semaglutide is solved by turning the dial up. A disappointing response may reflect poor protein intake, low training stimulus, erratic adherence, competing medications or unrealistic expectations. [2]

What most articles miss

A higher-dose trial is not merely about more kilograms lost. It is also about identifying who genuinely needs dose intensification. If a patient is already at a plateau but struggling more with muscle preservation or appetite volatility, escalating dose may be a clumsy answer when something else is the real problem.

Bottom line

STEP UP suggests semaglutide's efficacy ceiling may be higher than the currently familiar dose. But "more drug" is not a substitute for "better thinking." The right question is not only whether 7.2 mg works, but who actually needs it. [1,2]

FAQ

What did STEP UP show?
STEP UP showed semaglutide 7.2 mg achieved greater average weight loss than 2.4 mg and placebo. [1]
Does that mean 2.4 mg is obsolete?
No. For many patients 2.4 mg will remain adequate. The question is who benefits enough from escalation to justify it. [1,2]
Is higher-dose semaglutide automatically better?
Not in every case. Better efficacy can be offset by tolerability, adherence or body-composition issues. [1,2]
Why does STEP UP matter?
Because it shows the field is now competing at the margins of already strong efficacy. [1]
Should dose escalation be used after every plateau?
No. A plateau may reflect physiology, behaviour or diet quality rather than insufficient dose alone.

References

  1. STEP UP trial. Semaglutide 7.2 mg versus 2.4 mg for weight management. Data presented 2025.
  2. Wegovy (semaglutide) prescribing information. FDA. 2025.